SSRI vs. SNRI: Key Differences, Uses, and Side Effects

Selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are two of the most commonly prescribed types of antidepressants, and they work in closely related but distinct ways.

Both can treat depression and anxiety, but they affect different brain chemicals and are sometimes chosen for different symptoms. Understanding the difference can help you have a more informed conversation with your provider about which option fits your needs.

Key Takeaways

• The main difference is that SSRIs primarily affect serotonin signaling, while SNRIs affect both serotonin and norepinephrine signaling.

• Both can treat depression and anxiety: SNRIs are also used for certain types of chronic pain, such as nerve pain and fibromyalgia.

• SSRIs are usually tried first: They tend to be well tolerated, and the best choice depends on your symptoms, history, and how you respond.

What are SSRIs and SNRIs?

Both are classes of antidepressants that work on the brain’s chemical messengers (neurotransmitters), but they differ in exactly which ones they affect. Here is what each class is.

What are SSRIs?

SSRIs are a class of antidepressants that work by increasing the amount of serotonin available in the brain. Serotonin is a neurotransmitter, or chemical messenger, that helps regulate mood, sleep, appetite, digestion, and other functions. 

SSRIs block the reabsorption (reuptake) of serotonin by nerve cells, leaving more of it active in the brain. The increased serotonin is thought to affect multiple serotonin pathways in the brain that may contribute to the antidepressant effects of SSRIs. They are often the first medication tried for depression because of their safety and tolerability.

Common SSRIs include fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), citalopram (Celexa), and paroxetine (Paxil). They are used not only for depression but also for anxiety disorders, obsessive-compulsive disorder, and other conditions.

What are SNRIs?

SNRIs work in a similar way but act on two neurotransmitter systems instead of one. In addition to raising serotonin, they also increase norepinephrine, a neurotransmitter involved in energy, alertness, concentration, and the body’s stress response. 

Because SNRIs affect both serotonin and norepinephrine, some clinicians may consider them when depression occurs alongside fatigue, concentration difficulties, or chronic pain, although individual responses vary and evidence does not consistently show superiority for these symptoms.

Common SNRIs include duloxetine (Cymbalta), venlafaxine (Effexor XR), desvenlafaxine (Pristiq), and levomilnacipran (Fetzima). Notably, duloxetine is FDA-approved not only for major depression and generalized anxiety disorder but also for fibromyalgia, chronic musculoskeletal pain, and diabetic nerve pain.

How SSRIs and SNRIs are Similar

Before looking at the differences, it helps to recognize what these two antidepressant classes have in common. Both are reuptake inhibitors, meaning they keep certain brain chemicals active longer by blocking their reabsorption into the nerve cells. They share some broad similarities:

• Both raise serotonin: This action is why they can treat many of the same conditions and have some overlapping side effects.

• Both take time to work: Like most antidepressants, they usually need several weeks before the full benefit appears.

• Both are generally safer than first-generation antidepressants: SSRIs and SNRIs are second-generation antidepressants introduced in the late 80s and early 90s. Both classes are recommended as first-line treatments for depression and anxiety due to their better safety and side effect profile compared to tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs).

• Both are tapered, not stopped suddenly: Gradual discontinuation lowers the risk of antidepressant discontinuation syndrome with either class.

Although these common factors are shared between the two classes, there are differences between medications at an individual level. For e.g., clinical trials revealed that 30% of venlafaxine (Effexor XR) users experienced nausea compared to 15% of escitalopram (Lexapro) users, nausea being a serotonin-related side effect. 

SSRI vs. SNRI: The Main Differences at a Glance

Both classes share the same broad goal of improving communication between brain cells, but they differ in a few important ways:

These are general patterns, not strict rules. Individual response varies, and the same medication can work very differently from one person to another.

Conditions Each Class Treats

There is significant overlap in what SSRIs and SNRIs treat. Both are routinely prescribed for mood and anxiety disorders. Generally speaking, each class can be used to treat the following conditions:

• SSRIs: Frequently chosen for depression, generalized anxiety, panic disorder, social anxiety, OCD, and PTSD.

• SNRIs: Used for many of the same conditions, and also a common option when depression comes with fatigue, poor concentration, or chronic pain.

The choice often depends on symptoms, previous treatment response, coexisting medical conditions, side-effect considerations, and patient preferences. For instance, if tolerability to side effects is a concern based on response to earlier treatment, escitalopram (Lexapro) may be a safer choice, as it is better tolerated compared to other antidepressants. 

For people with comorbid hypertension, SSRIs may be more suitable, as SNRIs are associated with a risk of elevated blood pressure.

FDA-Approved Uses: A Closer Look

Within each class, individual medications carry their own set of FDA-approved uses, which is partly the reason why two drugs in the same family are not always interchangeable. The specific approvals can influence which medication a provider reaches for first. A few examples from clinical references and FDA labeling:

• Sertraline (Zoloft, an SSRI): Approved for major depressive disorder, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder, giving it one of the broadest profiles among antidepressants.

• Escitalopram (Lexapro, an SSRI): Approved for major depressive disorder (adults and adolescents 12 years and above) and generalized anxiety disorder (adults and children 7 years and above), and frequently used for overlapping anxiety conditions. 

• Duloxetine (Cymbalta, an SNRI): Approved not only for depression and generalized anxiety but also for fibromyalgia, chronic musculoskeletal pain, and diabetic nerve pain.

• Venlafaxine (an SNRI): Approved for major depressive disorder, generalized anxiety, panic disorder, and social anxiety disorder.

A medication can also be prescribed off-label, meaning for a condition outside its formal approval, when the clinical evidence supports it. FDA approval does not determine whether a medication can be effective for a particular condition, but approved uses generally have stronger regulatory review and may affect insurance coverage.

Side Effects and Discontinuation

The two classes share many side effects but differ in a few ways, including what happens when you stop. The sections below compare both.

Side Effects: How SSRIs and SNRIs Compare

The two classes share many of the same side effects, since both increase serotonin. Common effects can include nausea, headache, sleep changes, gastrointestinal disturbance, and sexual side effects, especially early in treatment. There are a few differences worth knowing:

• Blood pressure: Because SNRIs, especially venlafaxine and higher-dose regimens, also affect norepinephrine, they can raise blood pressure in some people, which providers may monitor.

• Dry mouth and sweating: These can be somewhat more common with SNRIs.

• Nausea and vomiting: Among the two classes, the SNRI venlafaxine (Effexor), has a comparatively higher risk of nausea and vomiting.

• Weight gain: SSRIs and SNRIs are associated with a risk of moderate weight gain, especially with long-term use. Among them, paroxetine (Paxil) has the highest risk of short-term and long-term weight gain. Fluoxetine (Prozac) is less likely to cause weight gain. 

• Serotonin syndrome: This rare but serious reaction can occur with either class, especially when combined with other medications that raise serotonin, so it is important to share your full medication list. Symptoms to watch for include: agitation, shivering, fever, excessively high heart rate and blood pressure, mental confusion, etc.

The SNRI desvenlafaxine is the active form of venlafaxine and is processed with relatively little involvement of the liver’s drug-metabolizing enzymes. This could mean a lower potential for drug interactions for some people.

Stopping Treatment: Why Half-Life Matters

One practical difference between specific antidepressants comes down to how quickly they leave the body, measured by a property called half-life. When a medication clears quickly, blood levels can drop sharply after a missed or stopped dose, which raises the chance of discontinuation symptoms.

Older reviews estimated that antidepressant discontinuation syndrome affects roughly 20% of people after abruptly stopping a medication taken for at least six weeks.

Moreover, discontinuation symptoms are more likely with both longer treatment and a shorter half-life. Common symptoms include flu-like feelings, dizziness or imbalance, nausea, sleep problems, and brief sensory disturbances some people describe as "brain zaps".

This pattern shows up across both classes rather than separating SSRIs from SNRIs cleanly:

• Shorter half-life, higher risk: The SNRI venlafaxine, with a half-life of 5 hours (immediate-release), is well known for discontinuation symptoms because it clears the body quickly. Among SSRIs, paroxetine carries a similar reputation for the same reason.

• Longer half-life, lower risk: Fluoxetine, an SSRI with a half-life of 2-4 days, stays in the body longer, so its levels fall gradually and discontinuation symptoms tend to be milder or less frequent.

• The general approach is a gradual taper: These symptoms are not a sign of addiction, and they can usually be avoided by lowering the dose slowly rather than stopping at once.

Because of this, providers generally recommend that either type of medication be tapered gradually rather than stopped suddenly. If you want to come off an antidepressant, your provider can map out a schedule that fits the specific drug you are taking.

What to Know Before Starting Either Medication

Whichever class you and your provider choose, a few things apply to both: 

• Give the medication time, since the full effect usually takes several weeks. With SSRIs and SNRIs, it is normal to feel things getting worse before symptoms start to improve.

• Take the medication consistently, preferably with food, at a fixed schedule.

• Report side effects rather than stopping or changing dosage on your own. Remember, most side effects get better within 1-2 weeks. 

• Share your complete list of medications and supplements, including over-the-counter products and herbal remedies like St. John’s Wort, because combinations that raise serotonin too much can be risky.

It is normal for the first choice not to be the perfect fit. Adjusting the dose or trying a different medication is a routine part of finding what works for you.

How Providers Choose Between an SSRI and an SNRI

There is no single "best" antidepressant; the right choice is personal. Providers weigh several factors, including your specific symptoms, any past response to medication, other health conditions, potential side effects, and possible interactions. 

SSRIs are commonly used as initial treatment and are effective for many individuals, although response varies. If an SSRI is not effective or not well tolerated, an SNRI is a common next step. 

If both classes do not produce sufficient response, there are other treatment options, including ones for severe depression and combined treatment with cognitive behavioral therapy. Finding the right fit sometimes takes more than one try, and that is a normal part of the process.

Medical Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice. Always talk with your physician or another qualified healthcare provider about any questions you have regarding a medical condition or your medications. If you are experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.

Sources

1. Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554406/ 

2. Mayo Clinic Staff. (2022, September 23). Antidepressants: Selecting one that's right for you. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046273 

3. Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. The Lancet, 373(9665), 746–758. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60046-5/abstract 

4. Singh HK, Saadabadi A. Sertraline. [Updated 2023 Feb 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547689/ 

5. Landy K, Rosani A, Estevez R. Escitalopram. [Updated 2023 Nov 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557734/ 

6. Dhaliwal JS, Spurling BC, Molla M. Duloxetine. [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549806/ 

7. Singh D, Saadabadi A. Venlafaxine. [Updated 2024 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535363/ 

8. Naseeruddin R, Rosani A, Marwaha R. Desvenlafaxine. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534829/ 

9. Wang, S. M., Han, C., Bahk, W. M., Lee, S. J., Patkar, A. A., Masand, P. S., & Pae, C. U. (2018). Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. Chonnam medical journal, 54(2), 101–112.           https://doi.org/10.4068/cmj.2018.54.2.101 

10. Warner, C. H., Bobo, W., Warner, C., Reid, S., & Rachal, J. (2006). Antidepressant discontinuation syndrome. American Family Physician, 74(3), 449–456. https://www.aafp.org/afp/2006/0801/p449 

11. Sohel AJ, Shutter MC, Patel P, et al. Fluoxetine. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459223/ 

12. Sheffler ZM, Patel P, Abdijadid S. Antidepressants. [Updated 2023 May 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538182/ 

13. Maline, J. (2025, March 27). SSRIs or SNRIs: Is one type of antidepressant better? Cleveland Clinic.                                              https://health.clevelandclinic.org/ssri-vs-snri 

14. Villines, Z. (2024, July 9). SSRI vs. SNRI: Differences, how they work, and side effects. Medical News Today.                     https://www.medicalnewstoday.com/articles/ssri-vs-snri 

15. National Institute of Mental Health. (2023, December). Mental health medications. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/topics/mental-health-medications